This led to the DIAmOND clinical trial, which is currently investigating the use of dual immunotherapy (durvalumab and tremelimumab) with trastuzumab in patients with advanced HER2-positive breast cancers [190]. This evidence concerns the gene ERBB2 and breast carcinoma.